Journal Home
Search for

Volume 41, Issue 4, Pages 251-254 (May 2010)


View previous. 7 of 16 View next.

Elevated Prevalence of Hepatitis B in Mexican Hemodialysis Patients. A Multicentric Survey

Ramón Paniaguaa, Angelina Villasís-KeeverbCorresponding Author Informationemail address, María del Carmen Prado-Uribea, María-de-Jesús Ventura-Garcíaa, Guadalupe Alcántara-Ortegaa, Samuel R. Ponce de Leonc, Nancy Cure-Boltb, Sigfrido Rangel-Fraustob

Received 12 January 2010; accepted 23 April 2010.

Background and Aims

The prevalence of hepatitis B virus (HBV) infection in patients on renal replacement has been reduced in developed countries, but information from developing nations is currently scarce and high prevalence rates are suspected. We undertook this study to analyze the prevalence of HBV infection and identify risk factors associated with it in a sample of Mexican hemodialysis patients.

Methods

A cross-sectional study was performed in patients on hemodialysis in Mexico. Adult patients from 10 hemodialysis centers were randomly selected. Patients answered a questionnaire for risk factors for HB infection and a blood sample was taken for HBsAg determination.

Results

We included 368 patients, 197 (53.5%) male, with a median age of 52 years (range: 18–93 years). In 26 patients HBsAg was positive with a prevalence of 7.1% (95% CI 4.4–9.7). Hepatitis C (HCV) was also tested, and 31 patients were positive with a prevalence of 8.4% (95% CI 5.5–11.2). Two patients (0.5%) were co-infected. Patients infected with HBV had been on hemodialysis longer (median time 50.5 months in HB positive vs. 34 months in HB negative; p = 0.005) and had history of more transfusions (median number of transfusions 5.5 vs 2; p < 0.009) compared with patients without HBV infection.

Conclusions

The prevalence of HBV infection in patients on maintenance hemodialysis in Mexico is about 7%, 35 times higher compared with the general population (0.2%).

(ARCMED-D-10-00017)

a Unit of Medical Investigation in Kidney Diseases, Instituto Mexicano del Seguro Social, México, D.F., México

b Research and Development, Bristol-Myers Squibb, México, D.F., México

c Laboratory of Biologics and Reagents of México, México, D.F., México

Corresponding Author InformationAddress reprint requests to: Angelina Villasis, MD, Area Head, Bristol Myers Squibb, Virology & Immunology, Av Revolucion No. 1267, Col. Tlacopac, Del. Alvaro Obregón, Distrito Federal, 01049, Mexico; Phone: (+52) (55) 5337-2834; FAX: (+52) (55) 5593-1956

PII: S0188-4409(10)00102-5

doi:10.1016/j.arcmed.2010.05.001


View previous. 7 of 16 View next.